Facebook
Twitter
LinkedIn
Forward
Traversing New Terrains In CLL: The Emerging Role Of BTK Inhibitors In The Treatment Landscape
The objective of this activity is to provide evidence-based information on the latest developments for the use of Bruton’s tyrosine kinase (BTK) inhibitors in patients with chronic lymphocytic leukemia (CLL). Given the demonstrated clinical benefit of BTKi therapy and its advantages over chemotherapy, it is essential for patients that the adoption of BTKi therapy continues to accelerate. Optimizing patient adherence to oral BTKis is vital to achieving efficacy and improving clinical outcomes. Hematology/oncology nurses must develop best practices for educating patients and monitoring adherence for those receiving oral BTKi therapy. Complicating the adherence landscape is the predominance of older patients with CLL, who are often on multiple medications and more complex regimens. As front-line caregivers, oncology nurses are optimally positioned to guide patients through therapy and properly manage adverse events that may arise with this therapy.
Supported by an independent educational grant from AstraZeneca.
Target Audience
This activity is designed to meet the educational needs of oncology nurses and nurse practitioners attending local ONS Chapter Meetings across the U.S.
Learning Objectives
- Describe the role of the B-cell receptor (BCR) pathway in the survival and proliferation of cancer cells and the rationale for targeting this pathway in CLL/SLL.
- Examine the latest efficacy data on the use of BTK inhibitors in treatment-naïve and relapsed/refractory CLL and review the most recent guideline recommendations for CLL/SLL management.
- Discuss the unique adverse events that may arise with the use of BTK inhibitors and explore evidence-based strategies to ensure the timely recognition and proper management of these adverse events.
Additional Information
| Attachment | Size |
|---|---|
 Handout and References | 2.08 MB |
| Zoom Guide | 420.08 KB |
5 min
Welcome and Introductions/Pre-test
10 min
Targeting the BCR Pathway in CLL: A Novel Approach
20 min
Contemporary Approaches to CLL: Taking a Deep Dive into BTK Inhibition
20 min
Applying Clinical Trial Data to Clinical Practice: Case-based CLL Treatment Strategies for the Oncology Nurse
5 min
Conversations with the Expert/Audience Q&A/Post-test
In-Person Location:
Perry’s Steakhouse & Grille
4251 Salzedo Street
Coral Gables, FL 33146
Virtual Location:
Zoom - Link Coming Soon!
Katherine L. Byar, MSN, ANP-BC, BMTCN Oncology Nurse Practitioner
Nebraska Medicine
Omaha, Nebraska
Ms. Byar is a Nurse Practitioner at the University of Nebraska Medical Center. She received her BS in Nursing from Nebraska Methodist College in Omaha and her Master of Science in nursing from the University of Nebraska Medical Center.
Ms. Byar has written several book chapters, co-authored numerous articles and posters and has lectured extensively on a variety of oncology nursing related topics. In addition, she is the recipient of several grants and awards for excellence in oncology nursing from both the Oncology Nursing Foundation and the American Cancer Society. Currently, she is a member of the ASCO University Editorial Board.
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Planner:
Vanessa Carranza, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Authors/Presenters:
Katherine L. Byar, MSN, ANP-BC, BMTCN—has no relevant financial relationships to disclose in relation to the content of this activity.
Amy L Goodrich, RN, MSN, CRNP-AC—has disclosed that she is a consultant for Gilead, Mylan, and Sandoz.
Barbara Rogers, CRNP, MN, AOCN, ANP-BC—has disclosed that she is a consultant for Cardinal Health, Genentech, and Merck. She is on the speakers' bureau for AbbVie, Genentech, and Seattle Genetics.
Reviewer:
Amy L. Goodrich, RN, MSN, CRNP-AC—has disclosed that she is a consultant for Gilead, Mylan, and Sandoz.
Barbara Rogers, CRNP, MN, AOCN, ANP-BC—has disclosed that she is a consultant for Cardinal Health, Genentech, and Merck. She is on the speakers' bureau for Abbvie, AstraZeneca, Coherus, and Genentech.
Bryan C. Taylor, PharmD - has no relevant financial relationships to disclose in relation to the content of this activity.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nursing (ANCC)
This activity is designated for 1.0 contact hour.
Upon completion of a CNE request form, statements of credit for nurses will be issued within 30 business days.
ONCC/ILNA Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. OCN®, AOCNP®, AOCNS®, CBCN®, CPHON®, and BMTCN® nurses may apply 1.0 point in Coordination of Care, Diagnosis and Staging, Disease-Related Biology, Oncology Nursing Practice, Professional Practice, Roles of the APN, Scientific Basis for Practice, Symptom Management, and Treatment categories.
Disclaimer: ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.
Available Credit
- 1.00 ANCC
- 1.00 Participation